Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTravere Therapeutics Inc

Travere Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
49.6 USD 0.73 ( 1.49%)
Last update at 2026-11-06T21:00:00Z
VOLUME
992329
Market Cap
5892.26M

Momentum Score

…

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
48.64
Low
50.45
High
52 Week Price Range
22.05
Low
68.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
48.87
Dividend Yield
-
Revenue TTM
591.33M
Revenue Per Share
6.48
Gross Profit TTM
350.12M
Debt / Equity
2.86
ROE
-236.36%
Net Debt
235.70M
ROCE
-8.65%
Diluted EPS TTM
-0.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -49.27M -320.51M -376.11M -278.17M -179.68M
Net income -25.55M -321.55M -111.40M -278.48M -180.09M
Selling general administrative 337.20M 264.12M 265.54M 220.21M 149.88M
Selling and marketing expenses - - 37.67M - -
Gross profit 480.39M 225.43M 133.79M 204.43M 220.71M
Reconciled depreciation 60.74M 43.55M 38.53M 33.08M 26.62M
Ebit -38.52M -309.33M -364.78M -251.56M -139.50M
Ebitda 22.22M -265.77M -326.25M -244.31M -137.28M
Depreciation and amortization 60.74M 43.55M 38.53M 7.25M 2.22M
Non operating income net other - - - -0.33M 2.22M
Operating income -62.82M -323.83M -388.14M -251.56M -139.50M
Other operating expenses 553.55M 557.00M 533.38M 463.58M 367.00M
Interest expense 10.75M 11.18M 11.33M 11.28M 20.14M
Tax provision 0.99M 0.12M 0.22M 0.31M 0.41M
Interest income 12.72M 17.82M 21.77M 6.28M 1.99M
Net interest income 1.97M 6.63M 10.43M -5.00M -18.15M
Income tax expense 0.99M 0.12M 0.22M 0.31M 0.41M
Total revenue 490.73M 233.18M 145.24M 212.02M 227.49M
Total operating expenses 543.21M 549.26M 521.93M 455.99M 360.21M
Cost of revenue 10.34M 7.74M 11.45M 7.59M 6.78M
Total other income expense net 13.55M 3.32M 12.03M -26.61M -40.18M
Net income from continuing ops -50.26M -320.63M -376.33M -278.48M -180.09M
Net income applicable to common shares - - - -278.48M -180.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 605.19M 594.12M 788.91M 672.59M 776.63M
Intangible assets 113.11M 103.22M 103.69M 145.04M 148.44M
Other current assets 28.76M 12.69M 19.34M 12.62M 6.47M
Total liab 490.36M 535.05M 588.10M 629.73M 474.52M
Total stockholder equity 114.83M 59.08M 200.81M 42.85M 302.11M
Other current liab 129.23M 100.32M 124.23M 108.46M 88.77M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -1472.71M -1447.17M -1125.62M -1014.22M -765.97M
Other liab - - - 84.52M 92.36M
Good will - 0.75M 0.80M 0.90M 0.94M
Other assets 0.75M - - 0.04M 11.07M
Cash 93.03M 58.53M 58.18M 61.69M 165.75M
Total current liabilities 159.90M 200.75M 177.91M 142.16M 124.09M
Current deferred revenue - 2.81M 7.10M 11.98M 16.27M
Net debt 235.70M 343.05M 346.61M 345.80M 96.23M
Short term debt 5.88M 74.08M 4.91M 4.43M 3.91M
Short long term debt - 68.68M - - -
Short long term debt total 328.73M 401.58M 404.78M 407.49M 261.99M
Other stockholder equity 1588.72M 1506.32M 1327.88M 1059.97M 1068.63M
Property plant equipment - - - 9.05M 11.11M
Total current assets 437.56M 416.70M 616.77M 486.44M 582.83M
Net tangible assets - - - -102.19M 153.68M
Short term investments 229.76M 312.17M 508.68M 388.56M 387.13M
Net receivables 80.13M 27.12M 21.18M 16.65M 16.16M
Long term debt 311.72M 310.31M 377.26M 375.55M 226.58M
Inventory 5.88M 6.20M 9.41M 6.92M 7.31M
Accounts payable 24.80M 23.53M 41.67M 17.29M 15.14M
Accumulated other comprehensive income -1.19M -0.08M -1.46M -2.91M -0.56M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -1014.22M -765.97M
Non currrent assets other 39.16M 53.82M 42.11M 11.06M 11.07M
Non current assets total 166.87M 177.42M 172.14M 186.15M 193.81M
Capital lease obligations 17.01M 22.60M 27.52M 31.94M 35.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 86.45M 99.33M 36.02M -3.40M -113.47M
Change to liabilities - - - 22.84M 22.32M
Total cashflows from investing activities 27.89M 99.33M 55.78M -32.55M -137.62M
Net borrowings -68.90M 0.00M 0.00M 95.04M 104.93M
Total cash from financing activities -33.47M 139.42M 218.75M 117.57M 231.68M
Change to operating activities - - - 14.65M 23.68M
Net income -25.55M -320.63M -376.33M -278.48M -180.09M
Change in cash 34.50M 0.36M -3.51M -104.06M 80.98M
Begin period cash flow 58.53M 58.18M 61.69M 165.75M 84.77M
End period cash flow 93.03M 58.53M 58.18M 61.69M 165.75M
Total cash from operating activities 37.78M -237.47M -280.02M -186.29M -14.79M
Issuance of capital stock 0.00M 134.74M 191.20M 19.55M 224.93M
Depreciation 60.74M 43.55M 38.53M 33.08M 26.62M
Other cashflows from investing activities -0.40M -0.04M 165.81M -28.97M -19.05M
Change to inventory 5.02M -3.77M -39.42M -2.06M -1.81M
Change to account receivables -27.82M -6.04M -11.30M -0.68M -0.06M
Sale purchase of stock - - - 27.11M 2.11M
Other cashflows from financing activities -2.10M 4.68M 27.55M 309.35M 4.64M
Change to netincome - - - 41.58M 23.19M
Capital expenditures 58.16M 101.21M 41.59M 28.56M 24.15M
Change receivables - - - -0.68M -0.06M
Cash flows other operating - - - -4.19M 81.80M
Cash and cash equivalents changes - - - -101.27M 79.27M
Change in working capital -14.00M -63.02M -25.48M 0.90M 79.98M
Stock based compensation 44.87M 36.91M 44.25M 39.18M 30.77M
Other non cash items -28.28M 65.71M 39.01M 19.03M 23.82M
Free cash flow -20.37M -338.69M -321.61M -214.85M -38.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TVTX
Travere Therapeutics Inc		 0.73
1.49%		 49.60 - 43.86 9.96 252.78 10.70 1095.09
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

3611 Valley Centre Drive, San Diego, CA, United States, 92130

888 969 7879

https://travere.com

497

Name Title Year Born
Dr. Eric M. Dube Ph.D. Pres, CEO & Director 1973
Ms. Elizabeth E. Reed Sr. VP, Gen. Counsel & Corp. Sec. 1971
Dr. William E. Rote Ph.D. Sr. VP of R&D 1963
Dr. Noah L. Rosenberg M.D. Exec. Advisor 1967
Mr. Christopher Cline C.F.A., CFA Chief Financial Officer 1984
Ms. Sandra Calvin VP, Corp. Controller & Principal Accounting Officer 1965
Ms. Charlotte Smith Sr. VP of Public Affairs NA
Mr. Casey Logan Sr. VP of Corp. & Bus. Devel. NA
Ms. Angela Giannantonio Sr. VP of HR NA
Mr. Peter Heerma Chief Commercial Officer 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…